Daniel Rivera Rivera, MD

Articles by Daniel Rivera Rivera, MD

Making Obesity Care Affordable: Patient Views on Deprescribing GLP-1 RAs

BySarah E. Vordenberg, PharmD, MPH,Ellah Bliler, BS,Daniel Rivera Rivera, MD,Garth W. Strohbehn, MD,Eli W. Carter, MPH,Dina H. Griauzde, MD, MSc, DABOM,A. Mark Fendrick, MD

May 6th 2026

Most surveyed individuals with obesity support lower-cost options for weight maintenance, which would allow better coverage for injectable incretin mimetics for weight management during active weight loss.

Daniel Rivera Rivera, MD

Articles by Daniel Rivera Rivera, MD

Making Obesity Care Affordable: Patient Views on Deprescribing GLP-1 RAs

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer